No significant relationship of other epigenetic gene mutations (KMT2D, KMT2C, EZH2, TET2, and ARID1A) to disease progression is shown in DLBCL (Supplementary Table 3). This evidence concerns the gene TET2 and diffuse large B-cell lymphoma.